CHESS2204: Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients

Sponsor
Huashan Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05538546
Collaborator
Fifth Hospital of Shijiazhuang City (Other), The Sixth Hospital of Qingdao (Other), The Sixth Hospital of Dalian (Other), The Third People's Hospital of Taiyuan (Other), The Fourth People's Hospital of Qinghai Province (Other), Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine (Other), The Fifth People's Hospital of Wuxi Affiliated Hospital of Jiangnan University (Other), Beilun Hospital of Chinese Medicine (Other), Gansu Wuwei Tumor Hospital (Other), The Affiliated Hospital of Xuzhou Medical University (Other), First Affiliated Hospital of Fujian Medical University (Other), The Third People's Hospital of Linfen City (Other), The First Affiliated Hospital of Xian Jiaotong University (Other), The Third Affiliated Hospital of Hebei Medical University (Other), The First Affiliated Hospital of Anhui Medical University (Other), Liuzhou Workers Hospital (Other), The First People's Hospital of Taicang (Other), Xinjiang Hospital of Chinese Medicine (Other), Taizhou People's Hospital (Other), Shenzhen Third People's Hospital (Other)
1,000
15

Study Details

Study Description

Brief Summary

Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count

150,000 are considered to have very low risk of having varices requiring treatment, but whether these patients can be followed up by repetition of this criteria lacks sufficient evidence. This study aimed to assess the value of Baveno VI criteria for following up and monitoring of varices needing treatment in patients with compensated cirrhosis.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Complete blood count
  • Diagnostic Test: Transient elastrography
  • Diagnostic Test: Endoscopy

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
The Value of Baveno VI Criteria for Screening and Monitoring of Varices Needing Treatment in Patients With Compensated Cirrhosis
Anticipated Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Cohort 1

Population: Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000) at baseline.

Diagnostic Test: Complete blood count
Complete blood count will be conducted at 12th month and 24th month from baseline.

Diagnostic Test: Transient elastrography
Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.

Diagnostic Test: Endoscopy
Endoscopy will be conducted at 12th month and 24th month from baseline.

Cohort 2

Population: Patients don't meet Baveno VI criteria (with a liver stiffness ≥ 20kPa or with a platelet count ≤150,000) at baseline, but don't have varices requiring treatment (proved by endoscopy at baseline)

Diagnostic Test: Complete blood count
Complete blood count will be conducted at 12th month and 24th month from baseline.

Diagnostic Test: Transient elastrography
Transient elastrography, and endoscopy will be conducted at 12th month and 24th month from baseline.

Diagnostic Test: Endoscopy
Endoscopy will be conducted at 12th month and 24th month from baseline.

Outcome Measures

Primary Outcome Measures

  1. The missing rate of Baveno criteria at 12th month follow-up visit [12 months from baseline]

    The number of patients with varices requiring treatment under endoscopy divided by the number of patients meet Baveno criteria at 12th month follow-up visit

Secondary Outcome Measures

  1. The missing rate of Baveno criteria at 24th month follow-up visit [24 months from baseline]

    The number of patients with varices requiring treatment under endoscopy divided by the number of patients meet Baveno criteria at 24th month follow-up visit

  2. Cumulative rate of decompensation events [24 months from baseline]

    The cumulative rate of decompensated events in all participants during the 24 months.

  3. Cumulative rate of gastrointestinal bleeding [24 months from baseline]

    The cumulative rate of gastrointestinal bleeding in all participants during the 24 months.

  4. Cumulative rate of 6-week death post gastrointestinal bleeding [24 months from baseline]

    The cumulative rate of death in 6 weeks post gastrointestinal bleeding in patients with gastrointestinal bleeding events during the 24 months.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients with liver cirrhosis diagnosed according to clinical or pathological criteria;

  2. No decompensation events in the past, no ascites shown by ultrasound, no significant abnormality in liver function and coagulation function;

  3. Willing to carry out routine diagnosis and treatment evaluation and follow-up liver stiffness test and gastroscopy;

  4. Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000) at baseline, or patients don't meet Baveno VI criteria (with a liver stiffness ≥ 20kPa or with a platelet count ≤150,000) at baseline, but don't have varices requiring treatment (proved by endoscopy).

  5. Voluntarily signed the informed consent.

Exclusion Criteria:
  1. Patients with liver carcinoma;

  2. Patients with portal vein thrombosis;

  3. Patients with varices requiring treatment confirmed by gastroscopy during the screening period;

  4. Patients who have received propranolol, ligation, sclerosis, splenectomy, transcatheter splenic arterial embolization, transjugular interhepatic portosystemicstent-shunt and other treatments to decrease portal hypertension in the past.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Huashan Hospital
  • Fifth Hospital of Shijiazhuang City
  • The Sixth Hospital of Qingdao
  • The Sixth Hospital of Dalian
  • The Third People's Hospital of Taiyuan
  • The Fourth People's Hospital of Qinghai Province
  • Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine
  • The Fifth People's Hospital of Wuxi Affiliated Hospital of Jiangnan University
  • Beilun Hospital of Chinese Medicine
  • Gansu Wuwei Tumor Hospital
  • The Affiliated Hospital of Xuzhou Medical University
  • First Affiliated Hospital of Fujian Medical University
  • The Third People's Hospital of Linfen City
  • The First Affiliated Hospital of Xian Jiaotong University
  • The Third Affiliated Hospital of Hebei Medical University
  • The First Affiliated Hospital of Anhui Medical University
  • Liuzhou Workers Hospital
  • The First People's Hospital of Taicang
  • Xinjiang Hospital of Chinese Medicine
  • Taizhou People's Hospital
  • Shenzhen Third People's Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wen-hong Zhang, Professor, Huashan Hospital
ClinicalTrials.gov Identifier:
NCT05538546
Other Study ID Numbers:
  • OASIS-CHESS
First Posted:
Sep 14, 2022
Last Update Posted:
Sep 14, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 14, 2022